Last Updated : May 15, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort ascending |
|---|---|---|---|---|---|---|
| Lotemax | Loteprednol etabonate | Post-operative inflammation following cataract surgery | Do not list | Complete | ||
| Jurnista | Hydromorphone hydrochloride | Pain, Chronic (moderate to severe) | Do not list | Complete | ||
| Abilify | Aripiprazole | Schizophrenia | Do not list | Complete | ||
| Simponi | Golimumab | Arthritis, Rheumatoid | List in a similar manner | Complete | ||
| Forteo | Teriparatide (rDNA origin) injection | Osteoporosis (in women), Severe | Do not list | Complete | ||
| Simponi | Golimumab | Arthritis, psoriatic | List in a similar manner | Complete | ||
| Simponi | Golimumab | Ankylosing spondylitis | List in a similar manner | Complete | ||
| Azarga | Brinzolamide and timolol maleate suspension | Glaucoma and ocular hypertension | List in a similar manner to other drugs in class | Complete | ||
| Soliris | Eculizumab | Paroxysmal nocturnal hemoglobinuria (PNH) | Do not list | Complete | ||
| Vyvanse | Lisdexamfetamine dimesylate | Attention deficit hyperactivity disorder | Do not list | Complete |
Last Updated : May 15, 2024